Angel Matthew 4

What Happened

• Matthew Angel, reported as a 10% owner of Tempest Therapeutics (TPST), acquired 231,482 shares on March 24, 2026. The transaction was reported as a purchase (code P) at $2.16 per share, for a total reported value of $500,001. The filing indicates the purchase was an open market or private purchase.

Key Details

• Transaction date and price: 2026-03-24, 231,482 shares at $2.16 each.
• Total value: $500,001.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote summaries:
  • F1: The shares are held by Factor Bioscience Inc. The reporting person is CEO and chairman of Factor and disclaims beneficial ownership except for any proportionate pecuniary interest.
  • F2: The filing reflects pro rata distributions of shares by Erigen LLC to its members after the reporting person's last Section 16 filing; that distribution was a change in form of ownership and did not require separate reporting.
• Filing timeliness: Form 4 was filed on 2026-03-25 (one day after the transaction), i.e., timely reported.

Context

• As a 10% owner and through an entity (Factor Bioscience), this acquisition may reflect institutional/entity-level ownership rather than a simple personal trade. The F1 disclosure indicates the reporting person’s ownership is via Factor and is limited to any pecuniary interest.
• Purchases by insiders can be informative, but they do not by themselves indicate the insider's motive or guarantee future stock performance.